Canaccord raised the firm’s price target on Fractyl Health (GUTS) to $8 from $6 and keeps a Buy rating on the shares. The firm said the company’s 3Q25 report was incremental following REMAIN-1 data in Sept which surprised to the upside. After digesting the data the firm increaed its POS to 70% from 60% and doubling our peak penetration to 2% from 1% for Revita ahead of a catalyst heavy 4Q25/1Q26.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GUTS:
- Fractyl Health’s Earnings Call Highlights Clinical and Financial Progress
- Fractyl Health, Inc.: Promising Clinical Data and Strong Financial Position Justify Buy Rating
- Fractyl Health, Inc.: Promising Clinical Data and Strategic Advancements Drive Buy Rating
- Fractyl Health Reports Q3 2025 Results and Strategic Progress
- Fractyl Health reports Q3 EPS (71c), consensus (32c)